Identify the Potential Impact of Genetic Engineering on the Future Course of Human Immunodeficiency Virus (Hiv)

2082 Words Apr 26th, 2012 9 Pages

Similar to how the twentieth century was the era of prosperity of computing, the twenty-first century is the DNA era. The silicon age brought about remarkable changes in how we as a species think, operate and communicate. A chain reaction occurred, for with the advancements of the computer revolution, came the rise in the genetic revolution – a revolution that will indefinitely do for life what computing did for information. During this modernized age, we are on the brink of being able to transform, manipulate, and create organisms for any number of productive purposes. “From medicine, to agriculture, to construction and even computing, we are within reach of an age when manipulating the genetic codes of various organisms,
…show more content…
This may result in these therapies not being developed at a rate that corresponds to their economic benefit (Brent D. Fulton, 2009). The use of such technology brings up three financial issues such that include the cost of the therapy, the uncertainty about the level of future healthcare cost savings that result from the therapy as well as weather the payer for the therapy will be the beneficiary of any future savings.


In the wake of genetic engineering and its uses becoming so prevalent in our society, many ethical concerns have been raise as well as legal issues. While proponents of its use lean towards the improvements it could add to the quality of life and life expectancy for HIV sufferers in whom antiviral drugs are no longer effective, critics claim that humans should not be tampered with by other humans and that the therapies of genetic engineering are not effective. They also claim it is a very expensive venture and it might not be viable unless a few necessary steps are taken. Those in support also rebut, and compare the use and cost of stem cell therapy to that of organ transplants and cord blood transplant therapies.
One such case that has led to a halt in the development of this treatment happened in 1998, when eighteen-year-old Jesse Gelsinger, who was suffering from a liver ailment, called ornithine transcarbolzylase deficiency, volunteered

Related Documents